Drug Trial Radar · NCT07189169
QA108 Phase III Study in Subjects With Intermediate AMD
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 8, 2025
Primary completion
Mar 1, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Smilebiotek Zhuhai LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.
Conditions
- Intermediate Age-Related Macular Degeneration
Interventions
QA108 granulesDrug
Take the medication as required for 24 weeks
QA108 granules placeboDrug
Take the medication as required for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in drusen areaTime frame: weeks 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.